DISCOVERY PLATFORM

The Vibe Pharmaceuticals team has developed an innovative platform to identify mechano-responsive molecules which can serve as new-generation musculoskeletal therapeutics. We use vibration as a form of low-magnitude mechanical signal (LMMS) to isolate protein molecules from mechano-sensitive cells which mediate anabolic effects in target tissues. In a refinement of our screening protocol, we further select molecules that are produced by young but not aged cells in response to mechanical signals. Depending on the cell system used, our technology can identify circulating anabolic mediators produced by a variety of target tissues, with broad application to medical disorders that cause loss of bone and muscle mass.

THERAPEUTIC CANDIDATE

Using a unique screening platform, the Vibe Pharmaceuticals team has isolated secreted vibration-induced bone-enhancing (Vibe) molecules, an example of which is the protein VB-102. Treatment with VB-102 in three mouse models of age-related osteoporosis resulted in a significant increase in bone formation. VB-102 functions as a strong anabolic agent where bone resorption is coupled to enhanced deposition of mineralized matrix. Presently, Vibe Pharmaceuticals is evaluating VB-102 and other Vibe molecules as candidates for further development as agents for the treatment of osteoporosis.